Ovarian sensitivity index is strongly related to circulating AMH and may be used to predict ovarian response to exogenous gonadotropins in IVF by Biasoni, Valentina et al.
RESEARCH Open Access
Ovarian sensitivity index is strongly related to
circulating AMH and may be used to predict ovarian
response to exogenous gonadotropins in IVF
Valentina Biasoni
1, Ambra Patriarca
1, Paola Dalmasso
2, Angela Bertagna
3, Chiara Manieri
3, Chiara Benedetto
1 and
Alberto Revelli
1*
Abstract
Background: Serum anti-Mullerian hormone (AMH) is currently considered the best marker of ovarian reserve and
of ovarian responsiveness to gonadotropins in in-vitro fertilization (IVF). AMH assay, however, is not available in all
IVF Units and is quite expensive, a reason that limits its use in developing countries. The aim of this study is to
assess whether the “ovarian sensitivity index” precisely reflects AMH so that this index may be used as a surrogate
for AMH in prediction of ovarian response during an IVF cycle.
Methods: AMH serum levels were measured in 61 patients undergoing IVF with a “long” stimulation protocol
including the GnRH agonist buserelin and recombinant follicle-stimulating hormone (rFSH). Patients were divided
into four subgroups according to the percentile of serum AMH and their ovarian stimulation was prospectively
followed. Ovarian sensitivity index (OSI) was calculated dividing the total administered FSH dose by the number of
retrieved oocytes.
Results: AMH and OSI show a highly significant negative correlation (r = -0.67; p = 0.0001) that is stronger than
the one between AMH and the total number of retrieved oocytes and than the one between AMH and the total
FSH dose.
Conclusions: OSI reflects quite satisfactory the AMH level and may be proposed as a surrogate of AMH assay in
predicting ovarian responsiveness to FSH in IVF. Being very easy to calculate and costless, its use could be
proposed where AMH measurement is not available or in developing countries where limiting costs is of primary
importance.
Background
In human in-vitro fertilization (IVF), the identification of
variables able to predict ovarian responsiveness to exo-
genous gonadotropins allows to individualize treatment
protocols optimizing results and reducing complications.
Over the last two decades, a number of clinical, endo-
crine and ultrasound-detectable parameters have been
proposed as markers of ovarian follicular reserve and as
predictors of ovarian responsiveness to hormonal stimu-
lation. Most of them, unfortunately, have limited predic-
tive value [1,2], that can be partially compensated by
combining different variables in multi-marker prediction
models [3].
Circulating anti-Mullerian hormone (AMH) is pre-
sently claimed to be the best marker of ovarian reserve
and ovarian responsiveness to stimulation. In fact, it
has resulted to be superior to patient’s age, basal folli-
cle-stimulating hormone (FSH), estradiol, inhibin B [4]
and at least comparable to antral follicle count (AFC)
[5] in predicting ovarian responsiveness to exogenous
gonadotropins. AMH’s predictive capacity on oocyte
yield is well estabilished; differently, its significance in
regard to oocyte quality and pregnancy potential is still
under debate, even if recent work shows a good corre-
lation between AMH levels and occurrence of a viable
pregnancy [6].
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labs and is quite expensive, a point that limits its use in
developing countries, where particular attention must be
paid to the economical aspects of IVF programs.
Ovarian sensitivity index (OSI) is an easily measurable
parameter for patients previ o u s l ys u b m i t t e dt oa tl e a s t
one IVF. That is, it can be obtained dividing the total
dose of exogenous gonadotropins by the number of
oocytes retrieved at ovum pick-up (OPU).
Aim of the present study is to assess whether OSI
accurately reflects AMH levels in IVF patients and
therefore could be proposed as a surrogate of AMH
measurement where AMH assay is not available.
Methods
Patients
The study included 61 women attending for the first time
the IVF program at the Physiopathology of Reproduction
and IVF Unit of S. Anna University Hospital between June
2009 and April 2010. All patients satisfied the following
criteria: age ≤ 40 years; BMI between 19 and 30 kg/m
2;
basal (day 3) FSH ≤ 10 UI/l and AFC ≥ 8; regular men-
strual cycles; no history of ovarian surgery, chemotherapy
or pelvic irradiation; no evidence of endocrine disorders
(normal prolactin, androgen and thyroid-stimulating
hormone levels); no hormonal therapy in the six months
preceding IVF. The study was authorized by the local ethi-
cal committee and a written informed consent was
obtained from all recruited subjects.
Ovarian stimulation protocol
In order to provide homogeneity to the study, all patients
received a “long” gonadotropin-releasing hormone
(GnRH)-agonist protocol. Buserelin (Suprefact, Hoechst,
Germany) nasal spray (800 mcg/day) was administered
for 10-14 days until complete pituitary desensitization
was documented by US examination and estradiol mea-
surement. Ovarian stimulation was then accomplished
administering recombinant follicle-stimulating hormone
(rFSH; Gonal F, Merck-Serono, Switzerland) at a daily
dose between 100 and 300 UI that was individually estab-
lished according to age, body mass index (BMI), basal
FSH, and AFC (Table 1). Ovarian response to stimulation
was monitored by transvaginal US examination plus
serum estradiol measurement every second day from sti-
mulation day 6. From day 6, the rFSH dose was adjusted
according to ovarian response. When at least two leading
follicles reached 18 mm diameter, a s.c. injection of
10.000 UI human chorionic gonadotropin (hCG; Gonasi
HP, IBSA, Switzerland) was administered, and OPU was
scheduled 36 hours later.
OPU was performed by experienced operators that
strictly adhered to the following criteria: (1) puncture all
follicles > 10 mm diameter; (2) completely aspirate
follicular fluid using a standard aspiration pressure
(Rocket Aspiration Pump, USA); (3) signal every pro-
blem encountered during OPU that could have affected
the chance to retrieve oocytes.
A single lumen Cook needle (Cook, Sydney, Australia)
was used in all OPUs and follicular fluids were immedi-
ately given to the biologist for oocyte identification and
retrieval. Using this procedure, oocytes were retrieved
from approximately 95% of the punctured follicles.
AMH measurement
A venous blood sample for AMH measurement was
taken approximately one month before the scheduled
IVF treatment, independently of the menstrual cycle
phase. Blood samples were centrifuged at 3500 cycles/
min for 10 min and sera were stored in sterile tubes
and kept at -30°C for a time period not exceeding
2m o n t h s .
AMH was measured using a commercially available
enzyme immunoassay kit (Immunotech Beckman Coul-
ter, UK) following the manifacturer’si n s t r u c t i o n s .T h e
lowest detection limit of this assay is 0.14 ng/mL.,
whereas the maximal intra- and inter-assay coefficients
of variation are 12.3% and 14.2%, respectively. In order
to minimize the chance of bias in the assay, all sera
were processed in double, during the same day, using
the same measurement kits, and by the same operator.
Ovarian sensitivity index (OSI) calculation
OSI was calculated by dividing the total administered
rFSH dose by the number of oocytes retrieved at OPU,
thus obtaining the FSH-to-retrieved oocyte ratio.
Statistical analysis
Data were expressed as mean ± SD or counts and per-
centages. Patients were divided into four subgroups
according to the circulating AMH level: below the 25
th
percentile (AMH 0.25-1.1 ng/ml, subgroup A), between
the 25
th and 50
th percentiles (AMH 1.2-1.6 ng/ml, sub-
group B), between the 50
th and 75
th percentiles (AMH
1.7-2.6 ng/ml, subgroup C), and above the 75
th percen-
tile (AMH 2.7-8.5 ng/ml, subgroup D).
Qualitative data were analyzed by means of Chi-square
or Fisher’s exact test. The normality assumption of the
quantitative measures was verified by Shapiro-Wilk test
and significance of between-group differences were
assessed using ANOVA or Kruskal Wallis rank test, as
appropriate. Pairwise comparisons of the groups were
performed with Bonferroni’s adjustment for multiple
comparisons. Spearman’s correlation test was used to
test the relationship between OSI and patients’ age,
BMI, AFC and circulating AMH. To analyze the correla-
tion between OSI and AMH a linear regression analysis
adjusted by age was also performed.
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Results
The mean age of the 61 patients included in the study
was 34.9 ± 3.5 years and the mean BMI was 22.5 ± 2.9
kg/m
2. Infertility causes were male factor (52.5% of
cases), unexplained (26.2%), tubal damage (14.8%) and
mixed factors (e.g. tubal factor plus male factor). The
mean basal FSH level was 6.8 ± 1.7 IU/l, and the mean
AFC was 15.2 ± 6.6. The mean AMH level in the
patients’ group was 2.3 ± 1.8 ng/ml.
The mean starting dose of rFSH was 198 ± 76 IU/day
and the mean total rFSH dose was 2355 ± 1076 IU. The
mean length of stimulation was 11.7 ± 1.7 days and the
peak serum estradiol level the day of hCG administra-
tion was 2766 ± 1089 pg/ml. A mean number of 9.6 ±
4.5 oocytes were collected, 73% of which were meioti-
cally mature. The overall fertilization rate was 91.8%,
and 90.2% of the cycles leaded to embryo development
and transfer in the uterus. Overall, the pregnancy rate
per cycle was 32.7% and the implantation rate was 20%.
The four subgroups, formed on the basis of the AMH
level, did not significantly differ for age, BMI, and infer-
tility duration (Table 2). AFC was progressively higher
from subgroup A to subgroup D; moreover, subgroup D
had a mean AFC value significantly higher that the
other subgroups (p < 0.0001). The number of retrieved
oocytes in subgroup D was significantly higher than in
subgroup A, but not significantly different vs. subgroups
B and C. The total administered rFSH dose and the OSI
showed the same trend of AFC, becoming progressively
lower from subgroup A to subgroup D, and being signif-
icantly lower in subgroup D than in the other three sub-
groups (p < 0.0001) (Table 2).
OSI was significantly correlated to age, but not to
BMI; it was also inversely correlated to AFC levels
(r = -0.59, p = 0.0001; Table 3). A highly significant
inverse correlation was observed between OSI and
AMH (r = -0.67, p = 0.0001), and was confirmed by
the multivariate linear regression (p = 0.028; Figure 1).
The correlation between OSI and circulating AMH
that was stronger than those existing between AMH
and the total number of oocytes (r = 0.41, p < 0.01),
and between AMH and the total FSH dose (r = -0.49,
p < 0.01).
Discussion
Ovarian stimulation is a key event in human IVF, and
choosing properly the initial dose of gonadotropins
may avoid a poor oocyte yield and, on the other side,
an excessive response with high risk of ovarian hyper-
stimulation syndrome (OHSS). In most IVF Units, the
individual dose to stimulate the ovary is tailored con-
sidering age, basal FSH level, ovarian volume and the
count of small antral follicles (AFC). Prediction models
that use these variables singularly or in combination
reach an acceptable, even if not optimal, level of accu-
racy in estimating ovarian responsiveness to exogenous
gonadotropins [1,3].
Table 1 Criteria to establish the starting daily dose of rFSH according to age, body mass index (BMI), basal FSH, and
AFC
Clinical characteristics rFSH starting dose (IU)
Age < 35 + normal BMI + basal FSH < 8 IU/L + AFC > 14 100 - 150
Age < 35 + BMI 25-30 + basal FSH < 8 IU/L + AFC > 14 200
Age 35-40 and/or basal FSH 8-10 IU/L and/or AFC 8-13 150 - 250
Age 35-40 and/or basal FSH 8-10 IU/L and/or AFC 8-13, BMI > 25 300
Patients above 40 years, with BMI > 30 or < 19, basal FSH levels > 10 IU/L and/or AFC < 8 were a priori excluded from the study.
Table 2 Clinical characteristics of patients subgrouped according to circulating AMH levels
Subgroup A
n=1 4
Subgroup B
n=1 3
Subgroup C
n=1 8
Subgroup D
n=1 6
p Significant comparisons
MH (ng/ml) 0.25-1.1 1.2-1.6 1.7-2.6 2.7-8.5
Age (years) 35.8 ± 2.9 34.7 ± 3.7 34.8 ± 3.7 34.1 ± 3.8 0.64
BMI (Kg/m
2) 22.7 ± 3.4 21.7 ± 1.9 22.8 ± 3.0 22.8 ± 3.2 0.69
AFC 10.3 ± 3.3 12.3 ± 3.6 14.6 ± 4.0 22.8 ± 6.9 0.0001* D vs. A, B, C
Total dose of rFSH (IU) 3255 ± 1058 2418 ± 866 2347 ± 1066 1525 ± 527 0.0001* D vs. A, B, C
Stimulation length (days) 12.5 ± 1.7 11.0 ± 1.2 11.7 ± 1.8 11.7 ± 2.0 0.17
N. of retrieved oocytes 7.0 ± 3.0 8.6 ± 3.3 10.5 ± 4.9 11.8 ± 4.7 0.02* A vs .D
Ovarian sensitivity index (IU) 798 ± 1128 337 ± 216 304 ± 319 153 ± 92 0.0001* D vs. A, B, C
Subgroup A: below the 25
th percentile (AMH 0.25-1.1 ng/ml); Subgroup B: between 25
th and 50
th percentiles (AMH 1.2-1.6 ng/ml); Subgroup C: between 50
th and
75
th percentiles (AMH 1.7-2.6 ng/ml); Subgroup D: above the 75
th percentile (AMH 2.7-8.5 ng/ml).
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introduced into the clinical practice, and is presently
considered the best marker of ovarian reserve [7], being
also related to the live birth rate in IVF [6]. AMH is a
dimeric glycoprotein belonging to the transforming
growth factor-beta (TGF-b) superfamily and is produced
by the granulosa cells of small preantral follicles [8]. Dif-
ferently from FSH and AFC, AMH is a direct expression
of the amount of small follicles that constitute the bulk
of ovarian reserve [9,10]. Furthermore, its serum levels
show a very low inter- and intra-cycle variability and are
independent of the menstrual cycle phase [11].
At present, however, automated assay methods for
AMH are not yet available, and the Elisa assays cur-
rently in use have a rather high variability [12]. These
assays are expensive and not yet available in all IVF
labs; their cost limits the possibility of using them in
many developing countries, where relevant efforts are
made to keep IVF programs as cheap as possible.
When a patient has been submitted at least once to
ovarian stimulation for IVF, ovarian sensitivity index
(OSI) can be easily calculated dividing the total adminis-
tered gonadotropin dose by the number of oocytes
retrieved at OPU. This ratio represents indeed the ovar-
ian resistance to gonadotropins, as the lower is FSH
dose, the higher is ovarian sensitivity. However, the
term “ovarian sensitivity index” appears to be more
immediate than “ovarian resistance” in recalling the idea
of ovarian sensitivity, and therefore has been adopted
herein.
T h ep r e s e n ts t u d ys h o w st h a tO S Id i s p l a y sas t r o n g ,
inverse correlation with AMH levels, and that this cor-
relation is stronger than those between AMH and the
total gonadotropin dose, or between AMH and the total
number of retrieved oocytes. This is not surprising as it
was shown that neither the total FSH dose administered,
nor the absolute number of oocytes accurately reflect
ovarian responsiveness to hormonal stimulation; their
ratio is much more accurate in describing how the
ovary produces oocytes in response to exogenous stimu-
lation [13].
According to our observations, OSI does not accu-
rately reflect the patient’sa g e ,e v e ni fi ts h o w saf a i r l y
good correlation with it (r = 0.40). It rather appears to
be partially independent on age: this suggests that it
could be incorporated in prediction models aimed at
predicting ovarian responsiveness to exogenous gonado-
tropins as a partially independent parameter.
Our data have been obtained using the GnRH-agonist
buserelin plus rFSH in a classical “long” protocol; it
must be remarked that the correlation between OSI and
AMH found herein could be slightly different in case a
different stimulation schedule or different drugs are
used. It has been reported, in fact, that rFSH stimulation
yields on the average more oocytes with a lower dose
compared to what happens using human menopausal
gonadotropin (hMG) [14].
In conclusion, the present study shows that OSI accu-
rately reflects AMH level of women submitted to IVF
with a “long” protocol. According to the present study,
OSI appears to be a highly reliable index of ovarian
responsiveness to rFSH and can be useful to estimate
the rFSH dose in all IVF cycles following the first, pro-
vided that the same kind of protocol is used. We have
studied herein a relatively small cohort of patients,
although quite homogeneous: obviously larger scale
(and maybe multicenter) studies are required to con-
clude that OSI may be used as a surrogate for AMH for
predicting the ovarian response in IVF. The possibility
that OSI could be a reliable surrogate of AMH mea-
surement is particularly interesting for IVF Units where
AMH assay is not yet available or is considered too
expensive to be introduced, e.g. in developing countries
where the economical cost of IVF program needs to be
limited.
Table 3 Correlation between ovarian sensitivity index
(OSI = FSH units per retrieved oocyte) and patients’ age,
BMI, antral follicle count (AFC) and circulating AMH
levels
rp
Age 0.40 0.0014
BMI 0.15 0.24
AFC -0.59 0.0001
AMH -0.67 0.0001
Figure 1 Correlation (multiple regression analysis) between
ovarian sensitivity index (OSI = FSH units per retrieved oocyte)
and circulating AMH levels. p = 0.028.
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